Latest News

AbbVie Stock Slips as Sales Miss Expectations And Bigger Challenges Await.

0

AbbVie Stock Slips as Sales Miss Expectations | Barron’s

Stock in AbbVie slipped after the drug company reported a higher profit than expected, while sales fell short.

The revenue shortfall may have reminded investors of a challenge


AbbVie

(ticker: ABBV) faces next year, when patent protection on its blockbuster arthritis drug Humira expires, allowing for competition from generic versions. Humira has achieved annual sales of $20.7 billion.

Quick To Enter the Market, Institutional Investors Now Shedding Single-Family Home Rentals

Previous article

Stay out of ‘Financial La La Land’: Suze Orman says most Americans need to do this now to survive their next crisis

Next article

You may also like

Comments

Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News